LIPOCINE
Lipocine Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. The company develops drugs based on Hydroance, a drug delivery technology. It primarily focuses on developing oral versions of several hormones for use in men and women health; and various respiratory products for cough and cold conditions. The company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. It also offers custom drugs for pharmaceutical/biotechnology companies. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
LIPOCINE
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1997-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.lipocine.com
Total Employee:
11+
Status:
Active
Contact:
8019947383
Total Funding:
66.72 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Srinivasan Venkateshwaran CTO and VP @ Lipocine
CTO and VP
Mahesh V. Patel President and CEO @ Lipocine
President and CEO
Stephen A. Hill Lead Director @ Lipocine
Lead Director
2014-01-01
Morgan Brown CFO @ Lipocine
CFO
Founder
Stock Details
Official Site Inspections
http://www.lipocine.com Semrush global rank: 4.12 M Semrush visits lastest month: 2.93 K
- Host name: 50-87-168-111.unifiedlayer.com
- IP address: 50.87.168.111
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Lipocine"
Lipocine Investor Room - Company Profile
Dec 17, 2024 Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for CNS disorders. Lipocine has …See details»
LIPOCINE INC. - Crunchbase Company Profile & Funding
Lipocine Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. The company develops drugs based on Hydroance, …See details»
Company - Lipocine
Innovative Pharmaceutical Products ENHANCING HEALTH & IMPROVING PATIENT COMPLIANCE. Become Part of The Change. AboutSee details»
Lipocine Inc. - LinkedIn
Lipocine Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. The company develops drugs based on Hydroance, a drug delivery technology.See details»
Careers - Lipocine
Excellent communication skills, problem solving, critical thinking, team and organization skills. About Lipocine. Lipocine Inc. is a biopharmaceutical company developing innovative pharmaceutical products for neuroendocrine and …See details»
Lipocine Inc. - AnnualReports.com
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline …See details»
Lipocine Inc. (LPCN) Company Profile & Facts - Yahoo Finance
See the company profile for Lipocine Inc. (LPCN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Lipocine Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The …See details»
Lipocine Inc. (LPCN) Company Profile & Overview - Stock Analysis
Feb 28, 2025 Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system …See details»
Lipocine Investor Room - Press Releases
Nov 18, 2024 Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. …See details»
Lipocine 2025 Company Profile: Stock Performance & Earnings
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and …See details»
Lipocine Announces FDA Labeling Changes for Testosterone …
Mar 12, 2025 Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of …See details»
Lipocine's Phase III trial of LPCN 1154 to begin for PPD
7 hours ago Lipocine CEO Mahesh Patel said: “We are excited to initiate this registration-enabling Phase III trial. “Importantly, based on Food and Drug Administration (FDA) protocol …See details»
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum ...
1 day ago Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today …See details»
Lipocine Announces Senior Leadership Appointments to Advance …
SALT LAKE CITY, Nov. 3, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary …See details»
Lipocine Inc. (LPCN): history, ownership, mission, how it works
Lipocine Inc. (LPCN) Mission Statement Company Overview Lipocine Inc. (LPCN) focuses on developing innovative pharmaceutical products using its proprietary Lip’ral drug delivery …See details»
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum ...
1 day ago Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 …See details»
Lipocine Announces FDA Labeling Changes for Testosterone …
Mar 12, 2025 Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated …See details»
Lipocine Announces Financial Results for the Third Quarter Ended ...
Sep 30, 2024 Lipocine is evaluating LPCN 1148 for the management of decompensated cirrhosis and has conducted a successful Phase 2 study that met its primary endpoint. The …See details»
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum ...
1 day ago lipocine inc: * lipocine announces initiation of outpatient phase 3 postpartum depression trial of lpcn 1154 * lipocine inc: patient dosing expected in q2/2025 source...See details»